Yahoo
Stockholm - Delayed Quote SEK

Diamyd Medical AB (publ) (DMYD-B.ST)

0.9960 -0.0080 (-0.80%)
At close: October 30 at 12:59:43 PM GMT+1
Chart Range Bar
Loading chart for DMYD-B.ST
  • Previous Close 1.0040
  • Open 0.9960
  • Bid 0.9970 x --
  • Ask 1.0080 x --
  • Day's Range 0.9880 - 1.0400
  • 52 Week Range 0.8960 - 17.8800
  • Volume 774,122
  • Avg. Volume 619,830
  • Market Cap (intraday) 154.365M
  • Beta (5Y Monthly) 2.20
  • PE Ratio (TTM) --
  • EPS (TTM) -2.0000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was incorporated in 1984 and is headquartered in Stockholm, Sweden.

www.diamyd.com

39

Full Time Employees

August 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

DMYD-B.ST
91.15%
OMX Stockholm 30 Index (^OMX)
13.47%

1-Year Return

DMYD-B.ST
90.33%
OMX Stockholm 30 Index (^OMX)
17.56%

3-Year Return

DMYD-B.ST
85.63%
OMX Stockholm 30 Index (^OMX)
59.03%

5-Year Return

DMYD-B.ST
94.26%
OMX Stockholm 30 Index (^OMX)
42.80%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -44.85%

  • Return on Equity (ttm)

    -97.63%

  • Revenue (ttm)

    477k

  • Net Income Avi to Common (ttm)

    -255.59M

  • Diluted EPS (ttm)

    -2.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    305.43M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -139.24M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: